What does this score mean?
The Confidence Index is not a treatment success rate; it is an editorial methodology score indicating the extent to which the scientific finding evaluated on this page can be relied upon. Study design, risk of bias, sample size, precision, direct applicability, reproducibility, transparency, and clinical relevance are evaluated together.
What did the study investigate?
It investigated the role of mitochondrial accumulation and lysosomal dysfunction in the formation of ‘mitochondrial plaques’ in Alzheimer’s biology.
How was it conducted?
APP/PSEN1/mt-Keima and 5xFAD mouse models monitoring mitophagy were used; findings were compared with postmortem human brain tissue obtained from Alzheimer’s patients.
What was found?
Mitochondrial accumulation and delayed lysosomal clearance were identified in neuronal processes; some structures were observed alongside amyloid, while others were independent of it.
Limitations of the study
The research is not a treatment trial; human data come from postmortem tissue and do not prove causal temporal sequence.
What does it mean clinically?
The study provides a strong research rationale to examine Alzheimer’s biology not only through amyloid, but also through mitochondrial and lysosomal quality control systems.
What do we not know yet?
It is not yet known how decisive this mechanism is at the onset of the disease and whether mitophagy/lysosome-targeted interventions will provide clinical benefit in humans.
Source
The full citation and links of the sources are preserved in the detailed evaluation section of this page.
Written and medically reviewed by: Dr. Kerem Çağlayan · Healthy aging and longevity · All Scientific Research
Detailed evaluation
Research evaluation · Source check: September 3, 2026
There is a notable new question in Alzheimer’s research: Could the inability to remove damaged structures from nerve cells in a timely manner affect the disease process just as much as their formation?
What did the study show?
The study by Xiuli Dan and colleagues, published in Nature Neuroscience on July 29, 2026, identified structures formed by mitochondria accumulating in neuronal processes as “mitochondrial plaques.” The research used the APP/PSEN1/mt-Keima mouse model to track mitophagy; similar structures were also observed in 5xFAD mice and in postmortem brain tissue obtained from Alzheimer’s patients.
Lysosomal recruitment following mitochondrial accumulation was delayed. Degradation could not be completed due to lysosomal dysfunction, resulting in the accumulation of mitochondria in both acidic and neutral environments. These structures could form mixed plaques together with amyloid, or they could appear independently of amyloid in early stages. Source study
Understanding the mitochondria–lysosome relationship
Mitochondria are at the center of cellular energy metabolism. Mitophagy is the cellular quality control process that selectively removes damaged or dysfunctional mitochondria. Lysosomes, on the other hand, contribute to completing recycling by degrading the transported material.
For this reason, merely initiating the clearance process is not sufficient; the degradation capacity at the final stage must also be functional. We can compare this to a recycling facility: Waste reaching the facility does not mean it has been processed and eliminated.
What does this mean in terms of amyloid and clinical treatment?
These findings do not negate the importance of amyloid; they support examining mitochondrial accumulation and the cellular clearance system within the same framework. The research is not a patient treatment trial. It does not present an intervention that reduces memory loss in humans, a clinical effect size, or treatment safety results. Postmortem tissue findings alone also do not prove the causal sequence of events in humans.
Connection to longevity research
Cellular energy production, mitophagy, autophagy, and lysosomal function are interconnected topics in healthy aging research. The intriguing approach here is to consider supporting energy production together with cellular maintenance capacity.
Strategies targeting NR/NMN, urolithin A, spermidine, trehalose, and the AMPK–TFEB pathways may come up in this discussion. However, interest at the mechanistic level does not mean efficacy in Alzheimer’s patients; no prescription or treatment recommendation for these products can be derived from this article.
Exercise, nutrition, and sleep patterns are evaluated within an individualized health plan. Intermittent fasting or caloric restriction should also not be turned into an automatic recommendation, especially for individuals experiencing weight loss and nutritional difficulties.
Message for patients and their loved ones
New research helps us understand the biology of Alzheimer’s in greater detail. In complaints of forgetfulness, personal evaluation and following the existing treatment plan are essential. This article is for informational purposes; it does not replace individualized diagnosis or treatment.
Source and reading note
Dan X, Croteau DL, Liu W et al. Mitochondrial accumulation and lysosomal dysfunction result in mitochondrial plaques in Alzheimer’s disease. Nature Neuroscience. July 29, 2026. DOI: 10.1038/s41593-026-02390-1 · PubMed record.
This evaluation is based on the accessible abstract and figure legends of the published article. Because sample sizes and numerical analyses in the full text were not independently verified, they are not presented here.
